EP1838291A4 - Pharmaceutical formulations and methods of use - Google Patents

Pharmaceutical formulations and methods of use

Info

Publication number
EP1838291A4
EP1838291A4 EP06718892A EP06718892A EP1838291A4 EP 1838291 A4 EP1838291 A4 EP 1838291A4 EP 06718892 A EP06718892 A EP 06718892A EP 06718892 A EP06718892 A EP 06718892A EP 1838291 A4 EP1838291 A4 EP 1838291A4
Authority
EP
European Patent Office
Prior art keywords
methods
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06718892A
Other languages
German (de)
French (fr)
Other versions
EP1838291A2 (en
Inventor
Rodney A Brown
Stephen H Curry
Michael Rubinstein
Michael R Violante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quay Pharmaceuticals Ltd
Pharmanova Inc
Original Assignee
Quay Pharmaceuticals Ltd
Pharmanova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36692870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1838291(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quay Pharmaceuticals Ltd, Pharmanova Inc filed Critical Quay Pharmaceuticals Ltd
Publication of EP1838291A2 publication Critical patent/EP1838291A2/en
Publication of EP1838291A4 publication Critical patent/EP1838291A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
EP06718892A 2005-01-21 2006-01-20 Pharmaceutical formulations and methods of use Withdrawn EP1838291A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64585705P 2005-01-21 2005-01-21
PCT/US2006/001887 WO2006078811A2 (en) 2005-01-21 2006-01-20 Pharmaceutical formulations and methods of use

Publications (2)

Publication Number Publication Date
EP1838291A2 EP1838291A2 (en) 2007-10-03
EP1838291A4 true EP1838291A4 (en) 2008-12-03

Family

ID=36692870

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06718892A Withdrawn EP1838291A4 (en) 2005-01-21 2006-01-20 Pharmaceutical formulations and methods of use

Country Status (12)

Country Link
EP (1) EP1838291A4 (en)
JP (1) JP2008528494A (en)
KR (1) KR20070116588A (en)
CN (1) CN101137352A (en)
AR (1) AR062647A1 (en)
AU (1) AU2006206423A1 (en)
BR (1) BRPI0614021A2 (en)
CA (1) CA2595470A1 (en)
IL (1) IL184735A0 (en)
MX (1) MX2007008833A (en)
TW (1) TW200640497A (en)
WO (1) WO2006078811A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2125021B8 (en) 2006-12-22 2012-02-15 Recordati Ireland Limited Combination therapy of lower urinary tract disorders with alpha 2delta ligands and nsaids
US8454993B2 (en) 2007-11-23 2013-06-04 Lupin Limited Controlled release pharmaceutical compositions of pregabalin
BRPI0819451A2 (en) * 2007-11-23 2017-10-03 Protect Pharmaceutical Corp PHARMACEUTICAL COMPOSITION, METHOD TO TREAT PAIN, PHARMACEUTICAL KIT, AND, USE OF A COMPOSITION
EP2661266B1 (en) 2011-01-07 2020-09-16 Anji Pharma (US) LLC Chemosensory receptor ligand-based therapies
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
PT2704698T (en) * 2011-05-05 2019-11-19 Hennig Arzneimittel Gmbh&Co Kg Dosage form for the controlled release of active ingredients
KR101438546B1 (en) * 2011-08-26 2014-09-17 근화제약주식회사 Controlled-release formulations comprising pregabalin
WO2013100873A1 (en) * 2011-12-19 2013-07-04 Mahmut Bilgic Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer)
AU2013207329B2 (en) 2012-01-06 2017-10-26 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
EP2800561B1 (en) 2012-01-06 2020-08-19 Anji Pharma (US) LLC Biguanide compositions and methods of treating metabolic disorders
KR102221846B1 (en) * 2014-04-07 2021-02-26 영진약품 주식회사 Pharmaceutical composition of pregabalin with improved stability and method for preparing thereof
JP6665099B2 (en) * 2014-08-29 2020-03-13 わかもと製薬株式会社 Lactic acid bacteria-containing composition
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3302425A4 (en) * 2015-05-26 2018-12-26 Isa Odidi Controlled extended release pregabalin
US11622938B2 (en) 2016-04-19 2023-04-11 Conaris Research Institute Ag Oral pharmaceutical compositions of nicotinamide
CA3030105A1 (en) * 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
JP6919119B2 (en) * 2017-01-23 2021-08-18 日新製薬株式会社 A compressed solid pharmaceutical composition containing a γ-aminobutyric acid derivative substituted at the 3-position.
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN112023032B (en) * 2020-09-14 2022-03-18 广东鼎信医药科技有限公司 Pharmaceutical composition containing digestive enzyme and preparation method thereof
JP2024504902A (en) 2020-12-04 2024-02-02 ラボラトリオス シラネス、エセ．ア．デ セ．べ． Coated stable solid pharmaceutical compositions of opioid analgesics and antiepileptic drugs for pain
CN116898819B (en) * 2023-06-09 2024-02-06 则正(上海)生物科技有限公司 Pregabalin sustained release agent and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781793A1 (en) * 1998-08-03 2000-02-04 Prographarm Lab PROCESS FOR PRODUCING COATED GABAPENTINE GRANULES
WO2006088814A2 (en) * 2005-02-15 2006-08-24 Jazz Pharmaceuticals Dosage form and method for sustained release of a substituted pyrazine compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
WO1998029095A2 (en) * 1997-01-03 1998-07-09 Elan Corporation, Plc Sustained release cisapride mini-tablet formulation
CN101410091A (en) * 2002-01-04 2009-04-15 Ivax研究公司 Drug delivery system for sustained delivery of glipizide
EP1490090A4 (en) * 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781793A1 (en) * 1998-08-03 2000-02-04 Prographarm Lab PROCESS FOR PRODUCING COATED GABAPENTINE GRANULES
WO2006088814A2 (en) * 2005-02-15 2006-08-24 Jazz Pharmaceuticals Dosage form and method for sustained release of a substituted pyrazine compound

Also Published As

Publication number Publication date
CA2595470A1 (en) 2006-07-27
CN101137352A (en) 2008-03-05
BRPI0614021A2 (en) 2011-03-01
TW200640497A (en) 2006-12-01
AU2006206423A1 (en) 2006-07-27
IL184735A0 (en) 2007-12-03
AR062647A1 (en) 2008-11-26
EP1838291A2 (en) 2007-10-03
KR20070116588A (en) 2007-12-10
WO2006078811A2 (en) 2006-07-27
MX2007008833A (en) 2008-03-25
JP2008528494A (en) 2008-07-31
WO2006078811A3 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
IL184735A0 (en) Pharmaceutical formulations and methods of use
HK1213814A1 (en) Diclofenac formulations and methods of use
EP1765379A4 (en) Pharmaceutical co-crystal compositions and related methods of use
ZA200802501B (en) Indenoisoquinolinone analogs and methods of use thereof
IL184563A (en) Pharmaceutical foam formulations and their uses
EP1933884A4 (en) Imaging agents and methods of use thereof
EP1890677A4 (en) Pharmaceutical compositions and use thereof
IL190885A0 (en) Immunogenic compositions and methods of use
IL189364A0 (en) Estrogen compositions and therapeutic methods of use thereof
IL182734A0 (en) 4-aminotetracyclines and methods of use thereof
EP1827391A4 (en) Dosage forms and methods of use thereof
IL191072A0 (en) Therapeutic compositions and methods
EP1909689A4 (en) Drug-containing implants and methods of use thereof
EP1979269A4 (en) Chlorite formulations, and methods of preparation and use thereof
EP1895991A4 (en) Modified release formulations of anti-irritability drugs
GB0516069D0 (en) Pharmaceutical and use thereof
IL185309A0 (en) Isoqunoline compounds and methods of use thereof
PL1655026T3 (en) Solid pharmaceutical formulations comprising diacereine and meloxicam
HK1109581A1 (en) Pharmaceutical use of graptopetalum and related plants
EP1968609A4 (en) Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds
PT1812072E (en) Benzothiazole formulations and use thereof
EP1906950A4 (en) Ansamycin formulations and methods of use thereof
IL190583A0 (en) Pth formulations and methods of use
IL186277A0 (en) Dnt-maleate and methods of preparation thereof
IL185575A0 (en) Benzoxazocines and their therapeutic use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070720

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VIOLANTE, MICHAEL, R.

Inventor name: RUBINSTEIN, MICHAEL

Inventor name: CURRY, STEPHEN, H.

Inventor name: BROWN, RODNEY, A.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: QUAY PHARMACEUTICALS LTD.

Owner name: PHARMANOVA INC.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20081104

17Q First examination report despatched

Effective date: 20090324

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090805